Literature DB >> 24322822

Levetiracetam results in increased and decreased alcohol drinking with different access procedures in C57BL/6J mice.

Eric W Fish1, Abigail E Agoglia, Michael C Krouse, R Grant Muller, J Elliott Robinson, C J Malanga.   

Abstract

The antiepileptic levetiracetam (LEV) has been investigated for the treatment of alcohol abuse. However, little is known about how LEV alters the behavioral effects of alcohol in laboratory animals. The acute effects of LEV on alcohol drinking by male C57BL/6J mice were investigated using two different drinking procedures, limited access [drinking-in-the-dark (DID)] and intermittent access (IA) drinking. In the first experiment (DID), mice had access to a single bottle containing alcohol or sucrose for 4 h every other day. In the second experiment (IA), mice had IA to two bottles, one containing alcohol or sucrose and one containing water, for 24 h on Monday, Wednesday, and Friday. In both experiments, mice were administered LEV (0.3-100 mg/kg intraperitoneally) or vehicle 30 min before access to the drinking solutions. In the DID mice, LEV increased alcohol intake from 4.3 to 5.4 g/kg, whereas in the IA mice LEV decreased alcohol intake from 4.8 to 3.0 g/kg in the first 4 h of access and decreased 24 h alcohol intake from 20 to ∼15 g/kg. These effects appear specific to alcohol, as LEV did not affect sucrose intake in either experiment. LEV appears to differentially affect drinking in animal models of moderate and heavier alcohol consumption.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24322822      PMCID: PMC3884554          DOI: 10.1097/FBP.0000000000000019

Source DB:  PubMed          Journal:  Behav Pharmacol        ISSN: 0955-8810            Impact factor:   2.293


  66 in total

1.  Efficacy and safety of levetiracetam for the prevention of alcohol relapse in recently detoxified alcohol-dependent patients: a randomized trial.

Authors:  Christoph Richter; Susanne Effenberger; Tom Bschor; Udo Bonnet; Christian Haasen; Ulrich W Preuss; Andreas Heinz; Anna Förg; Katharina Volkmar; Till Glauner; Martin Schaefer
Journal:  J Clin Psychopharmacol       Date:  2012-08       Impact factor: 3.153

Review 2.  Kindling as a model for alcohol withdrawal syndromes.

Authors:  J C Ballenger; R M Post
Journal:  Br J Psychiatry       Date:  1978-07       Impact factor: 9.319

3.  Evidence for the role of histamine H3 receptor in alcohol consumption and alcohol reward in mice.

Authors:  Saara Nuutinen; Minnamaija Lintunen; Jenni Vanhanen; Tiia Ojala; Stanislav Rozov; Pertti Panula
Journal:  Neuropsychopharmacology       Date:  2011-06-08       Impact factor: 7.853

4.  A new mechanism for antiepileptic drug action: vesicular entry may mediate the effects of levetiracetam.

Authors:  Anna L Meehan; Xiaofeng Yang; Brian D McAdams; Lilian Yuan; Steven M Rothman
Journal:  J Neurophysiol       Date:  2011-06-08       Impact factor: 2.714

5.  Agonism of the endocannabinoid system modulates binge-like alcohol intake in male C57BL/6J mice: involvement of the posterior ventral tegmental area.

Authors:  D N Linsenbardt; S L Boehm
Journal:  Neuroscience       Date:  2009-08-07       Impact factor: 3.590

6.  The influence of antiepileptic drugs on cognition: a comparison of levetiracetam with topiramate.

Authors:  Bettina Gomer; Kathrin Wagner; Lars Frings; Josef Saar; Astrid Carius; Markus Härle; Bernhard J Steinhoff; Andreas Schulze-Bonhage
Journal:  Epilepsy Behav       Date:  2007-04-03       Impact factor: 2.937

7.  II. Functional consequences of intragastrically administered ethanol in rats as measured by the 2-[14C]deoxyglucose method: the contribution of dopamine.

Authors:  L Williams-Hemby; L J Porrino
Journal:  Alcohol Clin Exp Res       Date:  1997-12       Impact factor: 3.455

Review 8.  Translating the neuroscience of alcoholism into clinical treatments: from blocking the buzz to curing the blues.

Authors:  Markus Heilig; Annika Thorsell; Wolfgang H Sommer; Anita C Hansson; Vijay A Ramchandani; David T George; Daniel Hommer; Christina S Barr
Journal:  Neurosci Biobehav Rev       Date:  2009-11-24       Impact factor: 8.989

9.  Comparative pharmacokinetics and metabolism of levetiracetam, a new anti-epileptic agent, in mouse, rat, rabbit and dog.

Authors:  M Strolin Benedetti; R Coupez; R Whomsley; J M Nicolas; P Collart; E Baltes
Journal:  Xenobiotica       Date:  2004-03       Impact factor: 1.908

Review 10.  Glutamatergic substrates of drug addiction and alcoholism.

Authors:  Justin T Gass; M Foster Olive
Journal:  Biochem Pharmacol       Date:  2007-06-30       Impact factor: 5.858

View more
  2 in total

Review 1.  Medications development for the treatment of alcohol use disorder: insights into the predictive value of animal and human laboratory models.

Authors:  Megan M Yardley; Lara A Ray
Journal:  Addict Biol       Date:  2016-02-01       Impact factor: 4.280

Review 2.  Rodent models and mechanisms of voluntary binge-like ethanol consumption: Examples, opportunities, and strategies for preclinical research.

Authors:  Brandon M Fritz; Stephen L Boehm
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2015-06-02       Impact factor: 5.067

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.